Pharmafile Logo

Living with NASH: An Unexpected Diagnosis

Published in eyeforpharma November 2017 by Mariel Metcalfe

With no current licensed treatments and more than 20 compounds in phase II and III, the liver disease non-alcoholic steatohepatitis (NASH) represents a huge opportunity for pharma companies – if they understand patient needs.

As our waistlines thicken and our activity levels decrease, another chronic illness threatens to disturb our comfortable lifestyles. And, because it’s relatively unknown, diagnosis comes as a shock to patients, who usually associate liver disease with heavy consumption of alcohol…

Read the full article: https://www.researchpartnership.com/news/2017/11/living-with-nash-an-unexpected-diagnosis/

This content was provided by Research Partnership

Company Details

 Latest Content from  Research Partnership 

The Next Billion Patients

Marc Yates, Director of Emerging Markets at pharma market research specialist Research Partnership, shares insights from his experience of working in BRIC and beyond.

Huge Untapped Growth Potential of ASEAN

Marc Yates, Director of Emerging Markets at pharma market research specialist Research Partnership, shares insights from his experience of working in BRIC and beyond.

The power of observation in gathering patient insights

Mary Assimakopoulos, Founding Director of global pharma market research specialist Research Partnership discusses how pharma can benefit from improved patient understanding.

Market Insights Can Deliver a Better Patient Experience

Mary Assimakopoulos, Founding Director of global pharma market research specialist Research Partnership discusses how pharma can benefit from improved patient understanding

Excellence in oncology: Developing an effective biomarker strategy

Oncology is arguably the most exciting area of medicine in which to be working today. Biomarkers and companion diagnostics offer incredibly valuable predictive power, which is of benefit to payers,...

Warehousing of HCV patients reaches new high

A new study conducted by Research Partnership reveals that 90% of physicians treating HCV patients in the US have reported they are now “warehousing” patients (holding off treatment) in expectation...

Brand leaders in RA will lose market share, predict rheumatologists

Rheumatologists believe that the current market for biologic treatments in Rheumatoid Arthritis (RA) will see key changes in the next three years.

Removing the Roadblocks to Effective Patient Treatment

How can pharma benefit from improved patient understanding? Welcome to a new column in which Mary Assimakopoulos, Founding Director of pharma market research specialist the Research Partnership reveals findings from...

Driving Earlier Diagnosis: A Case Study in Psoriatic Arthritis

Following a survey of 1000 Psoriatic Arthritis patients, Mary Assimakopoulos shares some of the root causes behind a late diagnosis of this debilitating illness, and the patients’ own feelings towards...

The Difficulties of Living with Depression Don’t End with the Illness Itself

This month Mary Assimakopoulos examines some of the insights gathered while surveying 2,000 patients suffering with this often misunderstood mental illness.